From Flow Cytometry to Transfection: Key Insights Driving Cell and Gene Therapy Innovation
Cell & Gene
The most valuable resource for professionals who make their living in the cell & gene therapies industry.
TRENDING CONTENT - Catch Up
Flow experiments must be controlled to produce consistent data. With a gush of new technology, regulators have put more scrutiny on flow cytometry-based approaches.
Complexity and manufacturability have an inverse relationship. Ring’s platform seeks to simplify highly complex gene therapy production by making the most of biology.
Confused about FDA's draft guidance on potency assays for cell and gene therapy products? Let's clarify a few things and discuss some key considerations.
#4. How To Identify And Quantify Adeno-Associated Virus Fill States Using Analytical Ultracentrifugation
Explore how to implement analysis using sedimentation velocity analytical ultracentrifugation to characterize AAV size distributions and multiple detection wavelengths to identify various fill states in AAV preparation.
Biotech companies in the US are increasingly choosing to conduct clinical trials in Australia. This is due to the "Australian Advantage", which offers U.S. biotech firms numerous benefits, including a cash rebate of almost 50%, faster timelines, no IND requirement, and globally accepted data.
Learn about the process of transfection and why it is crucial for studying gene function and has applications in various fields, including drug development and gene therapy.
Recommended by LinkedIn
CELL & GENE: THE PODCAST - Listen Here
Rita Johnson-Greene, MBA , COO at Alliance for Regenerative Medicine , joined Cell & Gene: The Podcast Host, Erin Harris , on-site during the #CGMesa24. Listen in as they discuss the Joint Clinical Assessment (JCA) in Europe and its potential impact on cell and gene therapies, how globalization impacts patient access, and an update on ARM's Grow Internship Program.
CELL & GENE LIVE! - Register Now
Unlocking the Full Potential of AAV-Mediated Gene Delivery
Tuesday, December 10, 2024 11:00 AM Eastern Standard Time 1 hour
Adeno-associated virus (AAV) vectors continue to be at the forefront of gene therapy innovation. Yet, despite significant advances, challenges remain in optimizing AAV-based treatments for broader clinical application.
In this Cell & Gene Live hosted by Cell & Gene 's Chief Editor, Erin Harris , we are honored to host two leading experts in the field: Susan Browne , Ph.D., Chief Development Officer at Passage Bio , and Nina Hunter , Ph.D., Vice President of Clinical Development at REGENXBIO . These pioneering companies share a rich history in AAV gene therapy with roots tracing back to the groundbreaking work of Dr. James Wilson. Browne and Hunter will discuss the latest developments in AAV vector design, manufacturing processes, and clinical strategies. They will also address key issues such as immunogenicity and regulatory considerations that are shaping the future of AAV gene therapies.